Biotechnology
11 articles
Insilico and SK Biopharm Advance AI Drug Discovery
Insilico Medicine's lead drug, INS018_055, reached Phase II trials in 2026, marking it as the first generative AI-designed drug for an AI-discovered target to achieve this milestone.
Altaris Capital Buys Simulations Plus for $375 Million
Simulations Plus shareholders will receive $18.
How AI is Accelerating Drug Discovery and Vaccine Development
In a remarkable acceleration, AI helped Insilico achieve a 30-month sprint from target identification to a Phase I clinical trial candidate, a process that traditionally takes years longer, according
AI autonomously generates cancer concepts from pathology images
An agentic AI framework named SPARK autonomously generated biological concepts from pathology images, validated across 18 cancer cohorts and over 5,400 patients, without requiring any manual feature e
What are AI advancements accelerating scientific discovery?
At a leading research institution, AI successfully reconstructed the intricate internal dynamics of heart cells by analyzing external signals, unveiling previously inaccessible biological insights.
AI accelerates Alzheimer's research into genetic targets
By age 65, almost all individuals with two copies of the APOE4 gene variant had abnormal levels of the Alzheimer's biomarker amyloid beta in their cerebrospinal fluid, according to NIH .
Cellular therapy market to reach $20B by 2030
The global cellular therapy market, valued at USD 4.
What Is Wetware AI? A Guide to Computers Powered by Living Brain Cells
Imagine a computer powered not by silicon chips, but by living human neurons. Wetware AI is an emerging field training brain cells for computational tasks, fundamentally rethinking what a computer can be.
Tech Outpaces Treaties: Why Global Counterterrorism Governance Is Insufficient
Existing global governance frameworks are insufficient for the counterterrorism challenges posed by emerging technologies like AI and biotechnology. A paradigm shift is urgently needed to prevent malign actors from exploiting this dangerous governance vacuum.
New Reports Detail Bioreactor and Lab-on-Chip Market Trends to 2030
New market analyses reveal significant trends in advanced bioprocessing, projecting the lab-on-chip market to reach $16.25 billion by 2030. These reports highlight key drivers, corporate acquisitions, and regional market dynamics for both lab-on-chip and fixed bed bioreactor systems.
Certis Oncology Launches AI-Powered Oncology Intelligence Platform
Certis Oncology has launched its new AI-powered Intelligence Platform, designed to advance cancer research by integrating predictive and agentic artificial intelligence with biological validation. This system aims to accelerate drug development and improve therapeutic response predictions.